Hedgehog Signaling in Myeloid Malignancies

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloid malignancies encompass diverse disorders originating from normal hematopoiesis.
• Aberrant activation of the Hedgehog (HH) signaling pathway is observed in numerous myeloid malignancies.
• Glasdegib, an HH pathway inhibitor targeting Smoothened (SMO), is approved for acute myeloid leukemia (AML).

Purpose of the Study:

• To elucidate the biological role of the HH pathway in normal hematopoiesis and myeloid malignancies.
• To review existing clinical studies targeting HH signaling in these hematologic disorders.
• To explore strategies for broadening the clinical application of HH pathway antagonists.

Main Methods:

• Review of biological roles of HH pathway in hematopoiesis.
• Analysis of clinical trial data for HH pathway inhibitors in myeloid malignancies.
• Examination of SMO-independent HH pathway activation mechanisms.

Main Results:

• The HH pathway plays a significant role in both normal blood formation and myeloid cancers.
• Clinical efficacy of SMO inhibitors like glasdegib is established in AML.
• Clinical studies in other myeloid malignancies have yielded inconclusive results regarding HH pathway inhibition.

Conclusions:

• Targeting the HH pathway holds promise for treating myeloid malignancies, particularly AML.
• Further research is needed to optimize HH pathway inhibition strategies for broader efficacy.
• Investigating SMO-independent activation is crucial for expanding therapeutic potential.